ADE (chemotherapy)

ADE is a chemotherapy regimen most often used as an induction or consolidation regimen in acute myelogenous leukemia, especially in poor-risk patients or those refractory to the standard first-line induction with standard "7+3" regimen or who are relapsed after the standard chemotherapy.

ADE regimen consists of three drugs:

  1. Ara-C (cytarabine) - an antimetabolite;
  2. Daunorubicin - an anthracycline antibiotic that is able to intercalate DNA and thus disrupt the cell division cycle, preventing mitosis;
  3. Etoposide - a topoisomerase inhibitor.[1]

Dosing regimen

Drug Dose Mode Days
Ara-C (cytarabine) 200 mg/m2 IV push every 12 hours in 2 divided doses (100 mg/m2 each) Days 1-10
Daunorubicin 50 mg/m2 IV slow push Days 1, 3 and 5
Etoposide 100 mg/m2 IV infusion over 1 hour Days 1-5

References

  1. ↑ Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.